Glycyl-H 1152 dihydrochloride
Cat. No. 2485
Chemical Name: (S)-(+)-4-Glycyl-2-methyl-1-[(4-met
Biological ActivityGlycyl analog of the Rho-kinase inhibitor H 1152 dihydrochloride (Cat. No. 2414) that displays improved ROCKII selectivity. IC50 values are 0.0118, 2.35, 2.57, 3.26, > 10 and >10 μM for ROCKII, Aurora A, CAMKII, PKG, PKA and PKC respectively.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Datasheet
References are publications that support the products' biological activity.
Tamura et al (2005) Development of specific Rho-kinase inhibitors and their clinical application. Biochim.Biophys.Acta 1754 245. PMID: 16213195.
If you know of a relevant reference for Glycyl-H 1152 dihydrochloride please let us know.
Citations are publications that use Tocris products. Selected citations for Glycyl-H 1152 dihydrochloride include:
Araki et al (2015) Rapid dispersion of SynGAP from synaptic spines triggers AMPA receptor insertion and spine enlargement during LTP. PLoS One 85 173. PMID: 25569349.
Lawrence et al (2015) Transport of organic anions and cations in murine embryonic kidney development and in serially-reaggregated engineered kidneys. Sci Rep 5 9092. PMID: 25766625.
Sadaie et al (2015) Cell-based screen for altered nuclear phenotypes reveals senescence progression in polyploid cells after Aurora kinase B inhibition. Mol Biol Cell 26 2971. PMID: 26133385.
Siegel et al (2010) Contribution of human amniotic fluid stem cells to renal tissue formation depends on mTOR. Hum Mol Genet 19 3320. PMID: 20542987.
View Related Products by Product Action
Keywords: Glycyl-H-1152 dihydrochloride, supplier, selective, Rho-Associated, Coiled-Coil, Kinases, ROCK, p160ROCK, ROK, Rho-Kinases, Tocris Bioscience, Rho-Kinases Inhibitor products
Find multiple products by catalog number
New Products in this Area
Inhibitor of Clk and DYRK kinasesEverolimus
mTOR inhibitor;immunosuppressantPKI (5-24)
High affinity PKA inhibitorTDZD 8
Selective non-ATP competitive inhibitor of GSK 3βBI 605906
Selective IKKβ inhibitorGSK 319347A
Potent and selective IKKε inhibitorFRAX 597
Potent group I PAK inhibitorMRT 68921 dihydrochloride
Potent ULK inhibitor; inhibits autophagyAM 2394
Potent glucokinase activator; orally bioavailableeCF 309
Potent mTOR inhibitorPF 3758309 dihydrochloride
Potent PAK4 inhibitor; orally availableAZ Dyrk1B 33
Potent and selective Dyrk1B kinase inhibitorPF 06409577
Potent and selective allosteric activator of AMPKPerifosine
PKB/Akt inhibitor; also modulates Kv2.1 currentRAF 265
Raf kinase and VEGFR-2 inhibitorCZC 25146
Potent LRRK2 inhibitorRo 3280
Potent and selective PLK1 inhibitorRMM 46
MSK/RSK family kinase inhibitorLTURM 34
Potent DNA-PK inhibitorMLi-2
Potent and selective LRRK2 inhibitorLTURM 36
PI 3-kinase δ inhibitorPI 3065
Potent and selective PI 3-kinase p110δ inhibitor
Follow Tocris on LinkedIn
Visit our LinkedIn page for the latest Tocris news, events and updates.